Pfizer Inc. (PFE:NYSE) closed at $28.64 on November 13, 2026, down 0.68% on the day. The stock trades 8.9% below its 52-week high of $31.44 and 21.2% above its 52-week low of $23.62. Over the past year, it gained 11.8%. Pfizer Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 12, 2025, PFE closed higher on 129 days (51%). Its best day was February 4, 2026 (+3.92%) and its worst was December 16, 2025 (-3.41%). It never moved 10% or more in a single session.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Me...
Find more stocks like PFE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.